U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H24F2N2O
Molecular Weight 322.3928
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-03654746

SMILES

CCNC(=O)[C@H]1C[C@](F)(C1)C2=CC(F)=C(CN3CCCC3)C=C2

InChI

InChIKey=SXMBKHYDZOCBMT-PPUGGXLSSA-N
InChI=1S/C18H24F2N2O/c1-2-21-17(23)14-10-18(20,11-14)15-6-5-13(16(19)9-15)12-22-7-3-4-8-22/h5-6,9,14H,2-4,7-8,10-12H2,1H3,(H,21,23)/t14-,18-

HIDE SMILES / InChI

Molecular Formula C18H24F2N2O
Molecular Weight 322.3928
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: http://www.pfizer.com/sites/default/files/product-pipeline/pipeline_2011_0228.pdf

PF-03654746 is a potent, selective antagonist of the human H3 receptor, developed by Pfizer. It was in the clinical trial phase II for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, Tourette syndrome as well as potential anti-allergy applications and in phase I of clinical trial for the treatment of Schizophrenia and Alzheimer's disease, but these investigations were discontinued.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14020 ng/mL
300 mg/kg 1 times / day multiple, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-03654746 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
189000 ng × h/mL
300 mg/kg 1 times / day multiple, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-03654746 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.7%
300 mg/kg 1 times / day multiple, oral
dose: 300 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
PF-03654746 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://clinicaltrials.gov/ct2/show/NCT01346163?term=PF-03654746&rank=4
excessive daytime sleepiness (EDS) associated with narcolepsy: Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days Schizophrenia: PF-03654746 will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:26 UTC 2023
Edited
by admin
on Fri Dec 15 16:02:26 UTC 2023
Record UNII
G3QE979K1X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-03654746
Common Name English
CYCLOBUTANECARBOXAMIDE, N-ETHYL-3-FLUORO-3-(3-FLUORO-4-(1-PYRROLIDINYLMETHYL)PHENYL)-, TRANS-
Common Name English
PF 03654746
Code English
Code System Code Type Description
EPA CompTox
DTXSID401029522
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
DRUG BANK
DB12201
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
ChEMBL
CHEMBL2151197
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
CAS
935840-31-6
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
FDA UNII
G3QE979K1X
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
WIKIPEDIA
PF-03654746
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
SMS_ID
300000041318
Created by admin on Fri Dec 15 16:02:26 UTC 2023 , Edited by admin on Fri Dec 15 16:02:26 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
ANTAGONIST
IC50
INTERMEDIATE -> INGREDIENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY